Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Jun 19;65(6):2401904.
doi: 10.1183/13993003.01904-2024. Print 2025 Jun.

Incident tuberculosis in people with HIV across Europe from 2012 to 2022: incidence rates, risk factors and regional differences in a multicentre cohort study

Affiliations
Multicenter Study

Incident tuberculosis in people with HIV across Europe from 2012 to 2022: incidence rates, risk factors and regional differences in a multicentre cohort study

Christian Kraef et al. Eur Respir J. .

Abstract

Background: Tuberculosis (TB) remains the leading cause of death among people with HIV. The aim of this study was to describe the incidence of TB, to explore risk factors and to calculate their population attributable fractions (PAFs) in people with HIV across Europe, stratified by region.

Methods: This was a longitudinal study of people with HIV aged ≥18 years with follow-up from either 1 January 2012 or cohort enrolment until date of a TB diagnosis, date of last visit, death or 31 December 2022. Factors associated with TB, in particular antiretroviral therapy status and smoking, were analysed using multivariable Poisson regression.

Results: A total of 38 837 participants with HIV had a median (interquartile range) follow-up of 7.7 (4.3-10.4) years. Overall, 306 TB cases were diagnosed during 275 811 person-years of follow-up (PYFU) (incidence rate 1.03 (95% CI 0.91-1.11) per 1000 PYFU). 3.3% (81/2428) of participants had incident TB in Eastern Europe (incidence rate 6.13 (95% CI 4.93-7.62) per 1000 PYFU). Overall, the incidence rate decreased from 2.03 (95% CI 1.53-2.68) per 1000 PYFU in 2012 to 0.44 (95% CI 0.20-0.97) per 1000 PYFU in 2022. Modifiable risk factors were smoking (adjusted incidence rate ratio (aIRR) 2.94, 95% CI 1.62-5.34) and not receiving antiretroviral therapy (versus on; aIRR 3.29, 95% CI 2.36-4.58). A history of TB pre-baseline increased the risk of recurrence (aIRR 7.77, 95% CI 4.09-14.74). The PAF for not receiving antiretroviral therapy was 34.6% in non-Eastern Europe and 31.2% in Eastern Europe.

Conclusions: TB incidence has been decreasing among people with HIV, but remains more frequent in Eastern Europe. Improvement of antiretroviral therapy coverage and adherence and a focus on non-communicable disease risk factors such as smoking could reduce the incidence of TB.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: C. Kraef received an honorarium for a lecture from Gilead. M. Knappik received grants, payment for lectures and travel support from Gilead Sciences, Merck Sharp & Dome and ViiV Healthcare GmbH, and participated in data safety monitoring and advisory boards for these companies. F. Wit received consulting fees from ViiV Healthcare, paid to his institution. M. Ballif reports grants from University of Bern and Inselspital, Switzerland. E. Wallner received grants, payment for lectures and travel support from Gilead Sciences, Merck Sharp & Dome and ViiV Healthcare GmbH, and participated in data safety monitoring and advisory boards for these companies. D. Israelski is an employee of Gilead Sciences. H. Garges is an employee of ViiV Healthcare. O. Kirk received honoraria for presentations at meetings supported by Gilead, Merck and ViiV, unconditional research grants from Gilead, and travel support from Gilead, Merck and ViiV. The remaining authors declare no competing interests.

Comment in

Publication types

LinkOut - more resources